Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OABI
OABI | US
2.62
USD0.01
0.38%
OABI | US
About OABI
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.62
Open
2.57
High
2.73
Low
2.55
OmniAb Inc. a biotechnology company engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals including OmniRat OmniChicken and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach and OmniTau which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville California.
View LessOABI | US
Risk
73.9
Sharpe
1.67
Luna's Score
66/100
Recommendation
Buy
Luna says (OABI | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
62.8%1 month
73.9%3 months
67.3%6 months
58.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.64
Debt to equity
0.08
Debt to assets
0.07
Ent. to EBITDA
-10.62
Ent. to rev.
20.69
PEG
-
Other Fundamentals
EBITDA
-62.02M
MarketCap
309.59M
MarketCap(USD)
309.59M
Div. yield
-
Op. margin
-247.29
Erngs. growth
-
Rev. growth
9.60
Ret. on equity
-19.87
Short ratio
19.70
Short perc.
7.70
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.54
Range1M
1.44
Range3M
1.44
Volumes: Market Activity
Rel. volume
0.68
Price X volume
1.82M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -10.62 | - | Cheaper |
| Ent. to Revenue | 20.69 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.64 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 67.33 | - | Par |
| Debt to Equity | 0.08 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 309.59M | - | Emerging |
